0000000000217003

AUTHOR

Etienne Cavalier

showing 6 related works from this author

Role of vitamin D supplementation in the management of musculoskeletal diseases: update from an European Society of Clinical and Economical Aspects o…

2022

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds…

AgingBone Density Conservation Agents610 Medicine & healthVitaminsFragility fractureVitamin D DeficiencyFractures BoneFalls Fragility fracture Osteoarthritis Vitamin DDietary SupplementsOsteoarthritisHumansOsteoporosisFallsGeriatrics and GerontologyVitamin D610 Medicine & healthAgedCalcifediolAging clinical and experimental research
researchProduct

Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations.

2022

© The Author(s) 2022 Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by…

not availableMotivationAnti-Inflammatory Agents Non-SteroidalQuality of LifeHumansPainPharmacology (medical)Osteoarthritis KneeArthroplasty Replacement KneeDrugs
researchProduct

Gut microbiota and osteoarthritis management: An expert consensus of the European society for clinical and economic aspects of osteoporosis, osteoart…

2019

Berenbaum, Francis/0000-0001-8252-7815; Dennison, Elaine/0000-0002-3048-4961; Bindels, Laure B./0000-0003-3747-3234; Cooper, Cyrus/0000-0003-3510-0709 WOS:000491638300002 PubMed ID: 31437484 The prevalence of osteoarthritis (OA) increases not only because of longer life expectancy but also because of the modern lifestyle, in particular physical inactivity and diets low in fiber and rich in sugar and saturated fats, which promote chronic low-grade inflammation and obesity. Adverse alterations of the gut microbiota (GMB) composition, called microbial dysbiosis, may favor metabolic syndrome and inflammaging, two important components of OA onset and evolution. Considering the burden of OA and t…

0301 basic medicineAgingmedicine.medical_specialtyOsteoporosisPsychological interventionOsteoarthritisGut microbiotaGut floraDysbiosis; Gut microbiota; Inflammaging; Modern diet; Obesity; OsteoarthritisBiochemistry03 medical and health sciences0302 clinical medicineOsteoarthritismedicineAnimalsHumansMusculoskeletal DiseasesObesityModern dietIntensive care medicineMolecular BiologySocieties MedicalInflammationbiologybusiness.industrymedicine.diseasebiology.organism_classificationObesityInflammagingDysbiosiInflammaging ObesityGastrointestinal MicrobiomeEurope030104 developmental biologyNeurologyOsteoporosisDysbiosisObservational studyOsteoarthritiMetabolic syndromebusinessDysbiosis030217 neurology & neurosurgeryBiotechnology
researchProduct

Novel formulations of oral bisphosphonates in the treatment of osteoporosis

2022

AbstractOral bisphosphonates are a key intervention in the treatment of osteoporosis and in reducing the risk of fragility fractures. Their use is supported by over 3 decades of evidence; however, patient adherence to oral bisphosphonates remains poor in part due to complex dosing instructions and adverse events, including upper gastrointestinal symptoms. This problem has led to the development of novel oral bisphosphonate formulations. Buffered, effervescent alendronate is dissolved in water and so seeks to reduce upper gastro-intestinal adverse events, and gastro-resistant risedronate aims to reduce the complexity of dosing procedure (e.g. fasting prior to consumption) whilst still mainta…

AgingDiphosphonatesAlendronateAlendronate/adverse effects610 Medicine & healthRisedronic Acid/therapeutic useDiphosphonates/adverse effectsFractures BoneHumansOsteoporosisAlendronate Bisphosphonates Fragility fracture Osteoporosis Risedronate TherapyGeriatrics and Gerontology610 Medizin und GesundheitBoneFracturesRisedronic AcidOsteoporosis/drug therapy
researchProduct

2021 revised algorithm for the management of knee osteoarthritis-the Chinese viewpoint.

2021

Abstract Aim The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) algorithm for the management of knee osteoarthritis (OA) is available worldwide from 2014, but in 2019 an update was published. Based on this algorithm, a Working Group (WG), including ESCEO members and Chinese experts, wished to see how the new ESCEO algorithm was perceived by Chinese experts in knee OA and how it was integrated into their clinical practice. Methods A WG was held between members of the international ESCEO task force and a group of Chinese experts. Results Non-pharmacological approach should be combined with pharmacological interventions. …

AgingChinaSymptomatic slow-acting drugs for osteoarthritisOsteoarthritis03 medical and health sciences0302 clinical medicineMedicineHumans030212 general & internal medicineKnee osteoartrhitis · Patented crystalline glucosamine sulfate · Symptomatic slow-acting drugs for osteoarthritis · Algorithm · ChinaConsensus Document030203 arthritis & rheumatologyGlucosamineKnee osteoartrhitisbusiness.industryGeriatrics gerontologyTask forceAnti-Inflammatory Agents Non-SteroidalChondroitin SulfatesPatented crystalline glucosamine sulfateOsteoarthritis Kneemedicine.diseaseClinical PracticeAlgorithmPharmacological interventionsGeriatrics and GerontologybusinessAlgorithmAlgorithmsAging clinical and experimental research
researchProduct

Guidelines for the conduct of pharmacological clinical trials in hand osteoarthritis: Consensus of a Working Group of the European Society on Clinica…

2017

Objectives To gather expert opinion on the conduct of clinical trials that will facilitate regulatory review and approval of appropriate efficacious pharmacological treatments for hand osteoarthritis (OA), an area of high unmet clinical need. Methods The European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal diseases (ESCEO) organized a working group under the auspices of the International Osteoporosis Foundation (IOF) and the World Health Organization (WHO). Results This consensus guideline is intended to provide a reference tool for practice, and should allow for better standardization of the conduct of clinical trials in hand OA. Hand OA is …

medicine.medical_specialtyConsensusStandardizationHand JointsOsteoporosisOsteoarthritisDiseaseGuidelinesArticle03 medical and health sciences0302 clinical medicineClinical trialsRheumatologyOsteoarthritisHand osteoarthritismedicineHumans030212 general & internal medicineIntensive care medicineClinical trials; Guidelines; Hand osteoarthritis; Pharmacological treatment030203 arthritis & rheumatologyClinical Trials as Topicbusiness.industryclinical trialmedicine.diseaseClinical trialAnesthesiology and Pain MedicineResearch DesignExpert opinionAntirheumatic Agentshand osteoarthritibusinessguidelinePharmacological treatmentHand osteoarthritisConsensus guideline
researchProduct